At the time of writing, Syndax Pharmaceuticals Inc [SNDX] stock is trading at $12.48, down -1.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SNDX shares have gain 25.05% over the last week, with a monthly amount glided 27.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on August 05, 2025, when BTIG Research reiterated its Buy rating and also boosted its price target to $56 from $43. Previously, Goldman started tracking the stock with Buy rating on July 10, 2025, and set its price target to $18. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $37 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $37 on June 28, 2024. Scotiabank downgraded its rating to a Sector Perform and reduced its price target to $23 on January 31, 2024. Mizuho started tracking with a Buy rating for this stock on December 22, 2023, and assigned it a price target of $45. In a note dated October 25, 2023, BofA Securities initiated an Buy rating and provided a target price of $29 on this stock.
For the past year, the stock price of Syndax Pharmaceuticals Inc fluctuated between $8.58 and $22.50. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $12.48 at the most recent close of the market. An investor can expect a potential return of 112.34% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
According to Syndax Pharmaceuticals Inc [NASDAQ:SNDX], the company’s sales were 78.18M for trailing twelve months, which represents an 984.51% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.34%, Pretax Profit Margin comes in at -4.28%, and Net Profit Margin reading is -4.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -1.3 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Syndax Pharmaceuticals Inc [NASDAQ:SNDX] has a current ratio of 4.71. In addition, the Quick Ratio stands at 4.55 and the Cash Ratio stands at 0.96. Considering the valuation of this stock, the price to sales ratio is 13.75, the price to book ratio is 6.82.
Transactions by insiders
Recent insider trading involved Goldan Keith A., Chief Financial Officer, that happened on Jul 16 ’25 when 1296.0 shares were sold. Chief Executive Officer, Metzger Michael A completed a deal on Jul 16 ’25 to sell 7534.0 shares. Meanwhile, Officer Goldan Keith A. bought 1296.0 shares on Jul 16 ’25.
